Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival

BACKGROUND: Immune checkpoint inhibitors have revolutionized cancer treatment, but the benefits in refractory patients with esophageal cancer have been modest. Predictors of response as well as new targets for novel therapeutic combinations are needed. In this phase 2 clinical trial, we tested singl...

Descripción completa

Detalles Bibliográficos
Autores principales: de Klerk, Leonie K, Patel, Anuj K, Derks, Sarah, Pectasides, Eirini, Augustin, Jeremy, Uduman, Mohamed, Raman, Nihal, Akarca, Fahire G, McCleary, Nadine J, Cleary, James M, Rubinson, Douglas A, Clark, Jeffrey W, Fitzpatrick, Bridget, Brais, Lauren K, Cavanaugh, Megan E, Rode, Amanda J, Jean, Melissa G, Lizotte, Patrick H, Nazzaro, Matthew J, Severgnini, Mariano, Zheng, Hui, Fuchs, Charles S, Enzinger, Peter C, Bass, Adam J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487210/
https://www.ncbi.nlm.nih.gov/pubmed/34593617
http://dx.doi.org/10.1136/jitc-2021-002472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487210/
https://www.ncbi.nlm.nih.gov/pubmed/34593617
http://dx.doi.org/10.1136/jitc-2021-002472

Ejemplares similares